To overcome this issue, we also established low passage tumor-derived cell cultures to test the efficacy of PI3K and AKT inhibitors based on identification of the activated AKT pathway by the phospho-array and confirmation by Western blot analysis. This evidence concerns the gene AKT1 and neoplasm.